PBAC's latest decision on Deucravacitinib: Deferred (2023). Considered for Treatment of severe chronic plaque psoriasis in patients who have not responded to or have a contraindication or demonstrated intolerance to methotrexate.
PBAC outcome
Deferred
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Adults aged 18 years or older with severe chronic plaque psoriasis who have not responded to, have a contraindication to, or have demonstrated intolerance to methotrexate, with significant interference to quality of life.
Therapy area
Dermatology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
sPGA 0/1 and PASI 75
Pivotal trial size
1,686 patients
Key trials
POETYK 1, POETYK 2
Comparator
apremilast
Economic model
CEA
ICER note
ICER not stated in the public document; the economic analysis was conducted but specific ICER values for deucravacitinib versus apremilast are not reported in this PSD.